Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Alethio clinches $90M to advance antibody for essential thrombocythemia

About a year after emerging from stealth, University of Oxford spinout Alethio Therapeutics has collected $90 million in a Series A raise to support its lead rare blood cancer program through ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in Health & Medicine

More from Thursday 5 November →